For nearly a year, the race for vaccines against Covid-19 has agitated the world. For the moment, the Pfizer-BioNTech vaccine was the first to be validated in Europe, closely followed by Moderna. If both use similar RNA technology, the way of preserving the second turns out to be simpler. In France, the Institut Pasteur threw in the towel in the development of its vaccine after disappointing results.
Sanofi claims to be able to supply more than 100 million doses
This Tuesday, January 26, in an interview with Figaro, the general manager of Sanofi, Paul Hudson, announced that his laboratory would help Pfizer-BioNTech to package its vaccine more simply: “We are going to use our Frankfurt plant in Germany to package the product that will be supplied to us by Pfizer-BioNTech from July. As this production site is located near the BioNTech headquarters, this will make things easier “.
He then explained: “Our teams are working together to put things in place under the right conditions, because this is a much more complex procedure than it seems. Vialing the vaccine must be done in a sterile environment and at very low temperature. ”The director of Sanofi assures that he will be able to provide more than 100 million doses by the end of the year. doses intended for the European Union.
Soon a new vaccine?
But, there is no question for Sanofi to give up on the development of its own vaccine. “We are continuing our work. Our recombinant protein vaccine is progressing well. This technology requires more time and we have a few more months of lead time, but we are confident. We succeeded in nine months which would have taken us 2 to 5 years in normal times “, summarizes Paul Hudson. He specifies that his laboratory should obtain” the first results on the dosage and the effectiveness in May, after which we can start our phase 3 “. The laboratory announces the objective of placing its vaccine on the market in the last quarter of the year.
COVID-19: WHEN WILL WE ALL BE VACCINATED?
To find out more about the coronavirus, the editorial staff invites you to discover its more complete and regularly updated articles:
- an article on Covid-19 disease and the evolution of the epidemic
- an article on the different screening tests
- an article on vaccines under development.